Treatment with sunitinib also resulted in reduced expression of IL-10, transforming growth factor-beta, and Foxp3, but increased expression of IFN-gamma, skewing the immune response toward a Th1 phenotype, and increased cytotoxic T lymphocyte (CTL) responses in isolated tumor infiltrating lymphocytes (TILs). The gene discussed is IFNG; the disease is neoplasm.